Literature DB >> 36266440

Individual-based modeling reveals that the COVID-19 isolation period can be shortened by community vaccination.

Chayanin Sararat1,2, Jidchanok Wangkanai1,2, Chaiwat Wilasang1,2, Tanakorn Chantanasaro1,2, Charin Modchang3,4,5,6.   

Abstract

The isolation of infected individuals and quarantine of their contacts are usually employed to mitigate the transmission of SARS-CoV-2. Although 14-day isolation of infected individuals could effectively reduce the risk of subsequent transmission, it also substantially impacts the patient's psychological and emotional well-being. It is, therefore, vital to investigate how the isolation duration could be shortened when effective vaccines are available. Here, an individual-based modeling approach was employed to estimate the likelihood of secondary infections and the likelihood of an outbreak following the isolation of a primary case for a range of isolation periods. Our individual-based model integrated the viral loads and infectiousness profiles of vaccinated and unvaccinated infected individuals. The effects of waning vaccine-induced immunity against infection were also considered. By simulating the transmission of the SARS-CoV-2 Delta (B.1.617.2) variant in a community, we found that in the baseline scenario in which all individuals were unvaccinated and nonpharmaceutical interventions were not used, there was an approximately 3% chance that an unvaccinated individual would lead to at least one secondary infection after being isolated for 14 days, and a sustained chain of transmission could occur with a less than 1% chance. With the outbreak risk equivalent to that of the 14-day isolation in the baseline scenario, we found that the isolation duration could be shortened to 7.33 days (95% CI 6.68-7.98) if 75% of people in the community were fully vaccinated with the BNT162b2 vaccine within the last three months. In the best-case scenario in which all individuals in the community are fully vaccinated, isolation of Delta variant-infected individuals may no longer be necessary. However, to keep the outbreak risk lower than 1%, a booster vaccination may be necessary three months after full vaccination.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36266440      PMCID: PMC9583066          DOI: 10.1038/s41598-022-21645-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  23 in total

1.  Covid-19: How the UK vaccine rollout delivered success, so far.

Authors:  Chris Baraniuk
Journal:  BMJ       Date:  2021-02-18

2.  Reduction in effective reproduction number of COVID-19 is higher in countries employing active case detection with prompt isolation.

Authors:  Chaiwat Wilasang; Chayanin Sararat; Natcha C Jitsuk; Noppamas Yolai; Panithee Thammawijaya; Prasert Auewarakul; Charin Modchang
Journal:  J Travel Med       Date:  2020-08-20       Impact factor: 8.490

3.  Impact on mental health by "Living in Isolation and Quarantine" during COVID-19 pandemic.

Authors:  Ankit Jain; Krishna Priya Bodicherla; Qasim Raza; Kamal Kant Sahu
Journal:  J Family Med Prim Care       Date:  2020-10-30

4.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.

Authors:  Nick Andrews; Julia Stowe; Freja Kirsebom; Samuel Toffa; Tim Rickeard; Eileen Gallagher; Charlotte Gower; Meaghan Kall; Natalie Groves; Anne-Marie O'Connell; David Simons; Paula B Blomquist; Asad Zaidi; Sophie Nash; Nurin Iwani Binti Abdul Aziz; Simon Thelwall; Gavin Dabrera; Richard Myers; Gayatri Amirthalingam; Saheer Gharbia; Jeffrey C Barrett; Richard Elson; Shamez N Ladhani; Neil Ferguson; Maria Zambon; Colin N J Campbell; Kevin Brown; Susan Hopkins; Meera Chand; Mary Ramsay; Jamie Lopez Bernal
Journal:  N Engl J Med       Date:  2022-03-02       Impact factor: 91.245

5.  Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies.

Authors:  Stephen M Kissler; Joseph R Fauver; Christina Mack; Scott W Olesen; Caroline Tai; Kristin Y Shiue; Chaney C Kalinich; Sarah Jednak; Isabel M Ott; Chantal B F Vogels; Jay Wohlgemuth; James Weisberger; John DiFiori; Deverick J Anderson; Jimmie Mancell; David D Ho; Nathan D Grubaugh; Yonatan H Grad
Journal:  PLoS Biol       Date:  2021-07-12       Impact factor: 9.593

6.  Effect of Vaccination on Household Transmission of SARS-CoV-2 in England.

Authors:  Ross J Harris; Jennifer A Hall; Asad Zaidi; Nick J Andrews; J Kevin Dunbar; Gavin Dabrera
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245

7.  SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Authors:  Aziz Sheikh; Jim McMenamin; Bob Taylor; Chris Robertson
Journal:  Lancet       Date:  2021-06-14       Impact factor: 79.321

8.  Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021.

Authors:  Min Kang; Hualei Xin; Jun Yuan; Sheikh Taslim Ali; Zimian Liang; Jiayi Zhang; Ting Hu; Eric Hy Lau; Yingtao Zhang; Meng Zhang; Benjamin J Cowling; Yan Li; Peng Wu
Journal:  Euro Surveill       Date:  2022-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.